408 related articles for article (PubMed ID: 26062020)
1. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
[TBL] [Abstract][Full Text] [Related]
2. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
Johansson A; Möller C; Fogh J; Harper P
Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
[TBL] [Abstract][Full Text] [Related]
5. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
[TBL] [Abstract][Full Text] [Related]
6. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
Sardh E; Harper P; Andersson DE; Floderus Y
Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
[TBL] [Abstract][Full Text] [Related]
7. Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.
Clavero S; Bishop DF; Haskins ME; Giger U; Kauppinen R; Desnick RJ
Hum Mol Genet; 2010 Feb; 19(4):584-96. PubMed ID: 19934113
[TBL] [Abstract][Full Text] [Related]
8. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec JY; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach JC; Puy H; Peoc'h K; Manceau H; Gouya L
J Intern Med; 2018 Jul; 284(1):78-91. PubMed ID: 29498764
[TBL] [Abstract][Full Text] [Related]
9. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
[TBL] [Abstract][Full Text] [Related]
10. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
Sardh E; Rejkjaer L; Andersson DE; Harper P
Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
[TBL] [Abstract][Full Text] [Related]
12. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.
Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ
Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812
[TBL] [Abstract][Full Text] [Related]
13. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
[TBL] [Abstract][Full Text] [Related]
14. AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.
Yasuda M; Bishop DF; Fowkes M; Cheng SH; Gan L; Desnick RJ
Mol Ther; 2010 Jan; 18(1):17-22. PubMed ID: 19861948
[TBL] [Abstract][Full Text] [Related]
15. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
Wang B; Bonkovsky HL; Lim JK; Balwani M
Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
[TBL] [Abstract][Full Text] [Related]
16. Cimetidine Does Not Inhibit 5-Aminolevulinic Acid Synthase or Heme Oxygenase Activity: Implications for Treatment of Acute Intermittent Porphyria and Erythropoietic Protoporphyria.
Yasuda M; Lee S; Gan L; Bergonia HA; Desnick RJ; Phillips JD
Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38254627
[TBL] [Abstract][Full Text] [Related]
17. Circadian rhythms in acute intermittent porphyria--a pilot study.
Larion S; Caballes FR; Hwang SI; Lee JG; Rossman WE; Parsons J; Steuerwald N; Li T; Maddukuri V; Groseclose G; Finkielstein CV; Bonkovsky HL
Eur J Clin Invest; 2013 Jul; 43(7):727-39. PubMed ID: 23650938
[TBL] [Abstract][Full Text] [Related]
18. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
